The project is part of the European Union Framework Program for Research and Innovation, Horizon 2020, and aims to promote innovation in the biopharmaceutical industry through co-operation with IT companies. The cooperation is supported by different kinds of vouchers. PERMIDES has a term of two years and has a total budget of almost 5 million euros.
Get funding for innovation partnerships to digitalize biopharmaceutical R&D
Advancing precision medicine in the digital age requires solutions developed in the IT and software sector, e.g. big data, machine learning, IT security, data protection, and cross-enterprise collaboration. The PERMIDES project aims at bringing together SMEs from the biopharmaceutical and IT sector to advance precision medicine through the development of novel digital solutions along the biopharmaceutical value chain. SMEs participating in the PERMIDES project can increase competitiveness and benefit from an innovation voucher scheme that will provide up to EUR 60,000 per project. About 90 innovation projects will be supported by the voucher scheme.
How can you as a SME benefit?
SMEs from the biopharmaceutical sector get access to relevant partners from the IT sector. The IT companies can develop and implement tailored digital solutions to improve business and product development processes. The costs incurred for this purpose by the IT partner will be covered by means of consulting, prototyping and customised solution vouchers totalling up to EUR 60,000. The biopharmaceutical company may also benefit from new products and applications developed by the IT company within the framework of the joint project. SMEs from the IT sector get access to partners and new customers from the biopharmaceutical sector to apply and adapt their solutions to SMEs developing novel personalized medicine products. Innovation vouchers will cover their expenses, and the knowledge gained during these projects may create new products and business opportunities.
PERMIDES has received funding from the European Union's Horizon 2020 research and Innovation programme under grant Agreement No 691546.